Hill-Rom Holdings Inc. (NYSE:HRC)’s share price gapped up prior to trading on Monday . The stock had previously closed at $57.85, but opened at $58.01. Hill-Rom Holdings shares last traded at $58.48, with a volume of 137,463 shares traded.

A number of research firms recently commented on HRC. Zacks Investment Research upgraded Hill-Rom Holdings from a “hold” rating to a “buy” rating and set a $64.00 price objective on the stock in a report on Tuesday, August 9th. KeyCorp reaffirmed a “buy” rating and set a $59.00 target price on shares of Hill-Rom Holdings in a research report on Thursday, June 23rd. Morgan Stanley raised Hill-Rom Holdings from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $54.00 to $62.00 in a research report on Thursday, June 16th. Finally, Bank of America Corp. reaffirmed a “buy” rating and set a $69.00 target price on shares of Hill-Rom Holdings in a research report on Monday, May 2nd. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Hill-Rom Holdings has a consensus rating of “Buy” and a consensus price target of $61.50.

The firm’s 50 day moving average is $52.60 and its 200-day moving average is $49.94. The firm has a market capitalization of $3.84 billion and a P/E ratio of 60.41.

Hill-Rom Holdings (NYSE:HRC) last issued its quarterly earnings data on Thursday, August 4th. The medical technology company reported $0.81 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.76 by $0.05. During the same quarter in the prior year, the firm posted $0.62 earnings per share. The business earned $655.40 million during the quarter, compared to analyst estimates of $647.75 million. Hill-Rom Holdings’s revenue for the quarter was up 38.1% compared to the same quarter last year. Equities analysts anticipate that Hill-Rom Holdings Inc. will post $3.33 EPS for the current fiscal year.

Other institutional investors have modified their holdings of the company. Trexquant Investment LP acquired a new position in shares of Hill-Rom Holdings during the fourth quarter valued at about $1,662,000. Marshall Wace LLP acquired a new position in shares of Hill-Rom Holdings during the fourth quarter valued at about $1,674,000. Mutual of America Capital Management LLC raised its position in shares of Hill-Rom Holdings by 1.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 38,072 shares of the medical technology company’s stock valued at $1,830,000 after buying an additional 593 shares in the last quarter. Matarin Capital Management LLC acquired a new position in shares of Hill-Rom Holdings during the fourth quarter valued at about $5,230,000. Finally, Bernzott Capital Advisors raised its position in shares of Hill-Rom Holdings by 16.5% in the fourth quarter. Bernzott Capital Advisors now owns 297,356 shares of the medical technology company’s stock valued at $14,291,000 after buying an additional 42,044 shares in the last quarter.

Hill-Rom Holdings, Inc is a medical technology company. The Company offers patient care solutions that improve clinical and economic outcomes in advancing mobility, wound care and prevention, clinical workflow, surgical safety and efficiency, and respiratory health areas. Its segments include North America, Surgical and Respiratory Care, International and Welch Allyn.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.